Andra AP fonden cut its position in HCP, Inc. (NYSE:HCP) by 18.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 208,800 shares of the real estate investment trust’s stock after selling 48,700 shares during the quarter. Andra AP fonden’s holdings in HCP were worth $5,391,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Global X Management Co LLC boosted its position in HCP by 15.1% during the second quarter. Global X Management Co LLC now owns 18,864 shares of the real estate investment trust’s stock worth $487,000 after purchasing an additional 2,481 shares during the period. Verition Fund Management LLC bought a new position in HCP during the second quarter worth $431,000. Putnam Investments LLC boosted its position in HCP by 5.5% during the second quarter. Putnam Investments LLC now owns 444,542 shares of the real estate investment trust’s stock worth $11,478,000 after purchasing an additional 23,015 shares during the period. Centaurus Financial Inc. bought a new position in HCP during the second quarter worth $256,000. Finally, Tower Research Capital LLC TRC bought a new position in HCP during the second quarter worth $605,000. 88.26% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have commented on the stock. Mizuho reaffirmed a “buy” rating and set a $29.00 price objective on shares of HCP in a research report on Monday, August 13th. Morgan Stanley reduced their price objective on shares of HCP from $28.00 to $23.50 and set an “equal weight” rating for the company in a research report on Thursday, June 14th. Capital One Financial reaffirmed an “equal weight” rating on shares of HCP in a research report on Monday, July 23rd. Robert W. Baird lifted their price objective on shares of HCP from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 9th. Finally, ValuEngine raised shares of HCP from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 26th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $26.46.

Shares of HCP stock opened at $25.70 on Tuesday. The stock has a market capitalization of $12.40 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 6.55 and a beta of 0.27. HCP, Inc. has a 52-week low of $21.48 and a 52-week high of $28.29. The company has a debt-to-equity ratio of 1.37, a current ratio of 0.51 and a quick ratio of 0.51.

HCP (NYSE:HCP) last announced its earnings results on Thursday, August 2nd. The real estate investment trust reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.27). The business had revenue of $469.60 million during the quarter, compared to the consensus estimate of $463.94 million. HCP had a net margin of 3.39% and a return on equity of 1.12%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 EPS. analysts anticipate that HCP, Inc. will post 1.82 earnings per share for the current year.

HCP Company Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Further Reading: Short Selling

Institutional Ownership by Quarter for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.